Is PCRX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for PCRX. It does not provide personalized investment advice.

PCRX (Pacira BioSciences, Inc. Common Stock) Stock Analysis - Financials

Pacira BioSciences, Inc. Common Stock (PCRX) is a publicly traded Healthcare sector company. As of September 4, 2026, PCRX trades at $26.72 with a market cap of $1.06B and a P/E ratio of 76.07. PCRX moved +0.46% today. Year to date, PCRX is +8.75%; over the trailing twelve months it is -0.49%. Its 52-week range spans $18.80 to $27.66. Analyst consensus is buy with an average price target of $28.80. Rallies surfaces PCRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are PCRX's key financials?

PCRX financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. PCRX recently traded at $26.72. Market cap is $1.06B. P/E ratio is 76.07. Revenue is $746.16M.

PCRX Key Metrics

Key financial metrics for PCRX
Metric	Value
Price	$26.72
Market Cap	$1.06B
P/E Ratio	76.07
EPS	$0.35
Dividend Yield	0.00%
52-Week High	$27.66
52-Week Low	$18.80
Volume	3.00K
Avg Volume	0
Revenue (TTM)	$746.16M
Net Income	$14.64M
Gross Margin	79.21%

PCRX Analyst Consensus

6 analysts cover PCRX: 0 strong buy, 3 buy, 2 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $28.80.

Common questions about PCRX

What are PCRX's key financials?: PCRX financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. PCRX recently traded at $26.72. Market cap is $1.06B. P/E ratio is 76.07. Revenue is $746.16M.
Is PCRX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for PCRX. It does not provide personalized investment advice.